Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience

February 13, 2020 Articles 7:21 pm

Today, ATAI Life Sciences, a global biotech platform that envisions an end to mental illnesses, announced the appointment of Dr. Terence Kelly as Chief Executive Officer of Perception Neuroscience, an ATAI biopharmaceutical company developing arketamine for treatment resistant depression.

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit